CU20180124A7 - Derivados de aminotiazol útiles como agentes antivíricos - Google Patents
Derivados de aminotiazol útiles como agentes antivíricosInfo
- Publication number
- CU20180124A7 CU20180124A7 CU2018000124A CU20180124A CU20180124A7 CU 20180124 A7 CU20180124 A7 CU 20180124A7 CU 2018000124 A CU2018000124 A CU 2018000124A CU 20180124 A CU20180124 A CU 20180124A CU 20180124 A7 CU20180124 A7 CU 20180124A7
- Authority
- CU
- Cuba
- Prior art keywords
- aminotiazol
- derivatives
- useful
- agent agents
- compounds
- Prior art date
Links
- RAIPHJJURHTUIC-UHFFFAOYSA-N 1,3-thiazol-2-amine Chemical class NC1=NC=CS1 RAIPHJJURHTUIC-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000036142 Viral infection Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 230000009385 viral infection Effects 0.000 abstract 2
- 241000700584 Simplexvirus Species 0.000 abstract 1
- 230000000840 anti-viral effect Effects 0.000 abstract 1
- 239000003443 antiviral agent Substances 0.000 abstract 1
- 229940121357 antivirals Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 241001529453 unidentified herpesvirus Species 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/54—Nitrogen and either oxygen or sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/44—Amides thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6536—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and sulfur atoms with or without oxygen atoms, as the only ring hetero atoms
- C07F9/6539—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- AIDS & HIV (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
<p>La invención se refiere a nuevos compuestos de Ia Fórmula (I)</p> <p>ESPACIO PARA FÓRMULA</p> <p>con un procedimiento para su preparación y con medicamentos que comprenden dichos compuestos, en particular medicamentos antivirales. Los nuevos compuestos son adecuados como compuestos antivirales en la profilaxis y tratamiento de enfermedades o trastornos asociados a infecciones víricas, en particular infecciones víricas causadas por el virus del herpes, en particular, el virus del Herpes simplex.</p>
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16000787 | 2016-04-06 | ||
| PCT/EP2017/058077 WO2017174640A1 (en) | 2016-04-06 | 2017-04-05 | Aminothiazole derivatives useful as antiviral agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20180124A7 true CU20180124A7 (es) | 2019-04-04 |
| CU24519B1 CU24519B1 (es) | 2021-06-08 |
Family
ID=55701658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2018000124A CU24519B1 (es) | 2016-04-06 | 2017-04-05 | Derivados de aminotiazol útiles como agentes antivíricos |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US10590094B2 (es) |
| EP (1) | EP3440063B1 (es) |
| JP (1) | JP6918823B2 (es) |
| KR (1) | KR102354411B1 (es) |
| CN (1) | CN109071473B (es) |
| AR (1) | AR108175A1 (es) |
| AU (1) | AU2017245679B2 (es) |
| CA (1) | CA3018026C (es) |
| CL (1) | CL2018002811A1 (es) |
| CO (1) | CO2018010689A2 (es) |
| CR (1) | CR20180482A (es) |
| CU (1) | CU24519B1 (es) |
| EA (1) | EA035401B1 (es) |
| EC (1) | ECSP18074962A (es) |
| ES (1) | ES2834051T3 (es) |
| GE (2) | GEP20207128B (es) |
| IL (1) | IL261421B2 (es) |
| MX (2) | MX375099B (es) |
| MY (1) | MY198018A (es) |
| PE (1) | PE20181804A1 (es) |
| PH (1) | PH12018501979B1 (es) |
| SV (1) | SV2018005760A (es) |
| TW (1) | TWI706940B (es) |
| UA (1) | UA123734C2 (es) |
| UY (1) | UY37193A (es) |
| WO (1) | WO2017174640A1 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107118207B (zh) * | 2017-05-22 | 2020-10-02 | 苏州东南药业股份有限公司 | 一类cdk抑制剂的制备方法 |
| DK3692039T3 (da) | 2017-10-05 | 2023-03-13 | Innovative Molecules Gmbh | Enantiomerer af substituerede thiazoler som antivirale forbindelser |
| US11760701B2 (en) | 2018-02-27 | 2023-09-19 | The Research Foundation For The State University Of New Yrok | Difluoromethoxylation and trifluoromethoxylation compositions and methods for synthesizing same |
| TW202038947A (zh) | 2018-11-28 | 2020-11-01 | 德商創新分子有限責任公司 | 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑 |
| MX2023004955A (es) | 2020-10-29 | 2023-05-17 | Innovative Molecules Gmbh | Compuestos de aminotiazol deuterados como compuestos antiviricos. |
| IL314188A (en) | 2022-01-17 | 2024-09-01 | Innovative Molecules Gmbh | Solid crystalline forms of helicase-primase inhibitors and process of preparation thereof |
| AU2023333337A1 (en) | 2022-08-29 | 2025-03-06 | Assembly Biosciences, Inc. | Cyclic urea thiazolyl compounds for treatment of hsv |
| CA3265860A1 (en) | 2022-08-29 | 2024-03-07 | Assembly Biosciences, Inc. | Pharmaceutical compositions against the herpes virus |
| CN121532378A (zh) | 2023-07-17 | 2026-02-13 | 创新分子股份有限公司 | 抗病毒解旋酶-引发酶抑制剂化合物的微粉化结晶盐酸盐 |
| WO2025111598A1 (en) | 2023-11-22 | 2025-05-30 | Assembly Biosciences, Inc. | Azetidine compounds for treatment of hsv |
| WO2026015761A1 (en) | 2024-07-12 | 2026-01-15 | Assembly Biosciences, Inc. | Cyclic urea thiazolyl compound for treatment of viral infections unresponsive to treatment with a first antiviral therapy |
| WO2026035901A1 (en) | 2024-08-07 | 2026-02-12 | Assembly Biosciences, Inc. | Tricyclic compounds for treatment of hsv |
| WO2026035900A1 (en) | 2024-08-07 | 2026-02-12 | Assembly Biosciences, Inc. | Tricyclic compounds for treatment of hsv |
| WO2026035899A1 (en) | 2024-08-07 | 2026-02-12 | Assembly Biosciences, Inc. | Azetidine compounds for treatment of hsv |
| CN121873064A (zh) * | 2024-10-17 | 2026-04-17 | 博远医药(苏州)有限公司 | 杂环类衍生物及其药物组合物和应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3847588A (en) * | 1970-04-20 | 1974-11-12 | Shell Oil Co | Thiazoles herbicidal |
| WO1997024343A1 (en) | 1995-12-29 | 1997-07-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Phenyl thiazole derivatives with anti herpes virus properties |
| US6040321A (en) * | 1997-11-12 | 2000-03-21 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
| AU3289299A (en) | 1998-02-19 | 1999-09-06 | Tularik Inc. | Antiviral agents |
| ATE229945T1 (de) | 1998-03-19 | 2003-01-15 | Upjohn Co | Zur behandlung von cmv infektionen geeignete 1,3, 4-thiadiazole |
| JP2002539119A (ja) | 1999-03-08 | 2002-11-19 | バイエル アクチェンゲゼルシャフト | チアゾリルウレア誘導体および抗ウイルス剤としてのそれらの使用 |
| DE19959958A1 (de) | 1999-12-13 | 2001-08-30 | Bayer Ag | Thiazolylharnstoff-Derivate |
| DE19927415A1 (de) | 1999-06-16 | 2000-12-21 | Bayer Ag | Indolinylharnstoffderivate |
| DOP2000000109A (es) * | 1999-12-23 | 2002-08-30 | Gerald Kleymann | Derivados de tiazolilamida |
| DE10039265A1 (de) | 2000-08-11 | 2002-02-21 | Bayer Ag | Thiazolylamid-Derivate |
| WO2001096874A1 (en) | 2000-06-15 | 2001-12-20 | Bayer Aktiengesellschaft | Method for identifying compounds with anti-herpes activity |
| DE10038022A1 (de) | 2000-08-04 | 2002-02-14 | Bayer Ag | Inverse Thiazolylamid-Derivate |
| DE10044358A1 (de) | 2000-09-07 | 2002-03-21 | Bayer Ag | Thiazolylcarbonylheterocyclyl-Derivate |
| DE10044353A1 (de) | 2000-09-07 | 2002-04-04 | Bayer Ag | Unkompetitive Inhibitoren der Helikase-Primase |
| DE10044328A1 (de) | 2000-09-07 | 2002-03-21 | Bayer Ag | Thiazolylcarbonyl-Derivate |
| DE10129717A1 (de) | 2001-06-22 | 2003-01-02 | Bayer Ag | Kombinationspräparate zur Herpes-Behandlung |
| DE10129716A1 (de) | 2001-06-22 | 2003-01-02 | Bayer Ag | Kombinationspräparate zur Herpes-Behandlung |
| DE10129715A1 (de) | 2001-06-22 | 2003-01-02 | Bayer Ag | Thiazolylamide |
| DE10129714A1 (de) | 2001-06-22 | 2003-01-02 | Bayer Ag | Topische Anwendung von Thiazolylamiden |
| DE10131128A1 (de) | 2001-06-28 | 2003-01-16 | Bayer Ag | Sekundäre Sulfonamide |
| DE10210319A1 (de) | 2002-03-08 | 2003-09-18 | Bayer Ag | Thiazolylcarbonyl-Derivate |
| DE10235967B4 (de) | 2002-08-06 | 2005-09-08 | Bayer Healthcare Ag | Methode zum Identifizieren von Substanzen mit antimikrobieller Wirkung |
| DE10300109A1 (de) | 2003-01-07 | 2004-07-15 | Bayer Healthcare Ag | Methode zur Inhibition der Replikation von Herpesviren |
| WO2005075435A1 (en) | 2004-01-30 | 2005-08-18 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
| DE102005014248A1 (de) | 2005-03-30 | 2006-10-05 | Aicuris Gmbh & Co. Kg | Pharmazeutische Zubereitung von N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamid |
| US8865185B2 (en) | 2006-09-08 | 2014-10-21 | The Trustees Of The University Of Pennsylvania | Methods of use for HSV-1 and HSV-2 vaccines |
| MX2013004724A (es) * | 2010-11-01 | 2013-08-29 | Romark Lab Lc | Compuestos de tiazolida alquilsulfinilo-sustituidos. |
| TW201636330A (zh) * | 2011-05-24 | 2016-10-16 | 拜耳知識產權公司 | 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺 |
| EP2573086A1 (en) * | 2011-09-26 | 2013-03-27 | AiCuris GmbH & Co. KG | N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate |
-
2017
- 2017-04-05 GE GEAP201714916A patent/GEP20207128B/en unknown
- 2017-04-05 UY UY0001037193A patent/UY37193A/es active IP Right Grant
- 2017-04-05 EP EP17715722.9A patent/EP3440063B1/en active Active
- 2017-04-05 PH PH1/2018/501979A patent/PH12018501979B1/en unknown
- 2017-04-05 AR ARP170100868A patent/AR108175A1/es active IP Right Grant
- 2017-04-05 MX MX2018012116A patent/MX375099B/es active IP Right Grant
- 2017-04-05 MY MYPI2018001585A patent/MY198018A/en unknown
- 2017-04-05 GE GEAP202014916A patent/GEAP202014916A/en unknown
- 2017-04-05 WO PCT/EP2017/058077 patent/WO2017174640A1/en not_active Ceased
- 2017-04-05 IL IL261421A patent/IL261421B2/en unknown
- 2017-04-05 ES ES17715722T patent/ES2834051T3/es active Active
- 2017-04-05 JP JP2018549786A patent/JP6918823B2/ja active Active
- 2017-04-05 TW TW106111352A patent/TWI706940B/zh active
- 2017-04-05 CU CU2018000124A patent/CU24519B1/es unknown
- 2017-04-05 PE PE2018001949A patent/PE20181804A1/es unknown
- 2017-04-05 EA EA201892246A patent/EA035401B1/ru not_active IP Right Cessation
- 2017-04-05 US US16/088,852 patent/US10590094B2/en active Active
- 2017-04-05 AU AU2017245679A patent/AU2017245679B2/en active Active
- 2017-04-05 KR KR1020187028938A patent/KR102354411B1/ko active Active
- 2017-04-05 CN CN201780022404.2A patent/CN109071473B/zh active Active
- 2017-04-05 UA UAA201810899A patent/UA123734C2/uk unknown
- 2017-04-05 CA CA3018026A patent/CA3018026C/en active Active
- 2017-04-05 CR CR20180482A patent/CR20180482A/es unknown
-
2018
- 2018-10-03 CO CONC2018/0010689A patent/CO2018010689A2/es unknown
- 2018-10-03 CL CL2018002811A patent/CL2018002811A1/es unknown
- 2018-10-04 EC ECSENADI201874962A patent/ECSP18074962A/es unknown
- 2018-10-04 SV SV2018005760A patent/SV2018005760A/es unknown
- 2018-10-04 MX MX2020005079A patent/MX2020005079A/es unknown
-
2020
- 2020-01-20 US US16/747,061 patent/US20200148652A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU24519B1 (es) | Derivados de aminotiazol útiles como agentes antivíricos | |
| ECSP18069924A (es) | Compuestos tetracíclicos de piridona como antivirales | |
| MX2022012616A (es) | Analogos de atazanavir (atv) para tratar infecciones por virus de inmunodeficiencia humana (vih). | |
| UY37710A (es) | Inhibidores de la replicación del virus de la inmunodeficiencia humana | |
| CO2017008403A2 (es) | Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos | |
| UY37124A (es) | Nuevos compuestos de 6,7-dihidro-5h-benzo[7]anuleno sustituidos, procesos para su preparación y usos terapéuticos de los mismos | |
| ECSP17072474A (es) | Métodos para tratar infecciones por el virus filoviridae | |
| UY35263A (es) | Compuestos terapéuticos | |
| MX2016014308A (es) | Compuestos y composiciones como agonistas del receptor tipo toll 7. | |
| CO2019009215A2 (es) | Sal hemi-sulfato de nucleótido para el tratamiento del virus de la hepatitis c | |
| UY36649A (es) | Inhibidores de la replicación del virus de la inmunodeficiencia humana | |
| NI201600144A (es) | Derivados de quinoxalina utiles como moduladores del fgfr cinasa | |
| UY36244A (es) | Derivados de la pirimidinona como inhibidores del factor xia y/o de la calicreína plasmática y composiciones farmacéuticas que los contienen | |
| MX2016013689A (es) | Compuestos 4-amino-imidazoquinolina. | |
| CU20190101A7 (es) | Imidazopirimidinas diazabicíclicas sustituidas | |
| DOP2016000278A (es) | Nuevos compuestos macrocíclicos | |
| CR20160558A (es) | Compuesto de 1, 3, 4 - tiadiazol y uso de los mismos para el tratamiento del cáncer | |
| MX2020003732A (es) | Derivado de anillo fusionado como inhibidor del receptor a2a. | |
| MX2019004347A (es) | Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y usos de los mismos. | |
| CR20150641U (es) | Composiciones farmacéuticas |